Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.
Precision Medicine at Fox Chase Cancer Center dates back to Hungerford’s discovery of the Philadelphia Chromosome, Daly’s creation of one of the first cancer family registries in the US, Knudson’s retinoblastoma two-hit hypothesis for tumor suppressor genes, and gene discoveries that predict risk such as Testa’s recent BAP1 discovery as a susceptibility gene for familial mesothelioma, uveal melanoma, and other tumors.
Efforts in the past decade have involved the development of in-house capabilities for genomic sequencing including Cancer-Code used in clinical practice. Additionally in the past five years there has been a broad range of precision medicine activities including identification of genomic biomarkers for bladder cancer response to chemotherapy, efforts to profile neuroendocrine cancers, and metastatic lesions in approximately 7000 colorectal cancers through our collaboration with Caris Life Sciences.
The goal of the precision medicine effort at Fox Chase Cancer Center is to investigate and direct relevant personalized interventions that impact on the health care of patients with cancer as well as those at increased risk for cancer. Several activities, both new and ongoing, are focused on those goals.